625 related articles for article (PubMed ID: 19135797)
1. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
2. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
3. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
4. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
5. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat.
Mills C; McMackin M; Jaffe R; Yu J; Zininberg E; Slee D; Gogas K; Bradbury M
Neuroscience; 2008 Sep; 156(1):165-74. PubMed ID: 18706981
[TBL] [Abstract][Full Text] [Related]
6. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
8. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
[TBL] [Abstract][Full Text] [Related]
9. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
11. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
12. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
Joshi SK; Honore P; Hernandez G; Schmidt R; Gomtsyan A; Scanio M; Kort M; Jarvis MF
J Pain; 2009 Mar; 10(3):306-15. PubMed ID: 19070548
[TBL] [Abstract][Full Text] [Related]
13. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
El Kouhen R; Surowy CS; Bianchi BR; Neelands TR; McDonald HA; Niforatos W; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2005 Jul; 314(1):400-9. PubMed ID: 15837819
[TBL] [Abstract][Full Text] [Related]
14. Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons.
Niiyama Y; Kawamata T; Yamamoto J; Omote K; Namiki A
Neuroscience; 2007 Aug; 148(2):560-72. PubMed ID: 17656027
[TBL] [Abstract][Full Text] [Related]
15. Analgesic potential of TRPV1 antagonists.
Kym PR; Kort ME; Hutchins CW
Biochem Pharmacol; 2009 Aug; 78(3):211-6. PubMed ID: 19481638
[TBL] [Abstract][Full Text] [Related]
16. Contributions of central and peripheral TRPV1 receptors to mechanically evoked and spontaneous firing of spinal neurons in inflamed rats.
McGaraughty S; Chu KL; Brown BS; Zhu CZ; Zhong C; Joshi SK; Honore P; Faltynek CR; Jarvis MF
J Neurophysiol; 2008 Dec; 100(6):3158-66. PubMed ID: 18829846
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists.
Drizin I; Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; DiDomenico S; Koenig JR; Turner SC; Jinkerson TK; Brown BS; Keddy RG; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter JM; Polakowski JS; Segreti JA; Jarvis MF; Faltynek CR; Lee CH
Bioorg Med Chem; 2006 Jul; 14(14):4740-9. PubMed ID: 16621571
[TBL] [Abstract][Full Text] [Related]
18. Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.
Rossato MF; Trevisan G; Walker CI; Klafke JZ; de Oliveira AP; Villarinho JG; Zanon RB; Royes LF; Athayde ML; Gomez MV; Ferreira J
Biochem Pharmacol; 2011 Feb; 81(4):544-51. PubMed ID: 21087598
[TBL] [Abstract][Full Text] [Related]
19. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1.
Gavva NR
Trends Pharmacol Sci; 2008 Nov; 29(11):550-7. PubMed ID: 18805596
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans.
Gavva NR; Treanor JJ; Garami A; Fang L; Surapaneni S; Akrami A; Alvarez F; Bak A; Darling M; Gore A; Jang GR; Kesslak JP; Ni L; Norman MH; Palluconi G; Rose MJ; Salfi M; Tan E; Romanovsky AA; Banfield C; Davar G
Pain; 2008 May; 136(1-2):202-10. PubMed ID: 18337008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
